European Cardiac Resynchronization Therapy Survey II: rationale and design by Dickstein, Kenneth et al.
CLINICAL RESEARCH
Clinical trial design
European Cardiac Resynchronization Therapy
Survey II: rationale and design
Kenneth Dickstein1*, Camilla Normand2, Stefan D. Anker3, Angelo Auricchio4,5,
, Nigussie Bogale , John Cleland ,6 2 7
Gerasimos Filippatos8, Maurizio Gasparini9, Anselm Gitt10, Gerhard Hindricks11,
Karl-Heinz Kuck12, Piotr Ponikowski13, Christoph Stellbrink14, Frank Ruschitzka15
and Cecilia Linde16
1University of Bergen, Stavanger University Hospital, Bergen and Stavanger, Stavanger, 4011 Norway; 2Stavanger University Hospital, Stavanger, Norway; 3Department of Innovative
Clinical Trials, University Medical Centre Go¨ttingen (UMG), Go¨ttingen, Germany; 4Clinical Electrophysiology Unit, Fondazione Cardiocentro Ticino, Lugano, Switzerland; 5University
Magdeburg,Germany; 6Institutionof Medical Science, Uppsala UniversityHospital, Uppsala, Sweden; 7ImperialCollege, London, UK; 8Athens UniversityHospitalAttikon,Athens, Greece;
9Humanitas ResearchHospital IRCCS, Rozzano, Italy; 10UniversityofHeidelberg, Heidelberg, Germany; 11Universityof Leipzig, Leipzig, Germany; 12Departmentof Cardiology,Asklepios-
Klinik St. Georg, Lohmuehlenstr 5, 20099 Hamburg, Germany; 13Wroclaw University, Wroclaw, Poland; 14Department of Cardiology and Intensive Care Medicine, Klinikum Bielefeld,
Teutoburger Strasse 50, 33604 Bielefeld, Germany; 15University Hospital in Zurich, Switzerland; and 16Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
Received 30 July 2014; accepted after revision 15 October 2014; online publish-ahead-of-print 17 November 2014
The Cardiac Resynchronization Therapy (CRT) Survey II is a 6 months snapshot survey initiated by two ESC Associations,
the European Heart Rhythm Association and the Heart Failure Association, which is designed to describe clinical practice
regarding implantation of CRT devices in a broad sample of hospitals in 47 ESC member countries. The large volume of
clinical and demographic data collected should reflect current patient selection, implantation, and follow-up practice and
provide information relevant for assessing healthcare resource utilization in connection with CRT. The findings of this
survey should permit representative benchmarking both nationally and internationally across Europe.
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Background
The benefits of cardiac resynchronization therapy (CRT) on clinical
outcomes in patients with symptomatic heart failure and electrical
dyssynchrony are convincing.1– 7 Therefore, current guidelines give
strong recommendations for CRT in patients who do not respond
sufficiently to medical therapy.8,9 However, implantation rates in
most countries do not reflect adequate implementation of current
guideline recommendations. Further efforts are therefore warranted
to describe current clinical practice and permit benchmarking across
Europe.
Cardiac Resynchronization Therapy Survey II is a 6 months snap-
shot survey to assess current clinical practice with regard to CRT
in a large sample size from a broad geographical area. The survey
will capture essential logistical and procedural details in connection
with consecutive CRT-P/CRT-D implantations and provide informa-
tion permitting centres and countries to benchmark their practice
with national and international practice. Data on important safety
measures and major short-term events associated with CRT
implantations during the index hospitalization will be reported with
long-term follow-up in a subset. The details of centre routines includ-
ing facilities, device activity profiles, and reimbursement policies, as
well as patient selection, implantation practice and outcomes in indi-
vidual patients will provide information permitting assessment of
health resource utilization and identification of the obstacles to
adequate CRT implementation at individual centres and countries.
The first Cardiac Resynchronization
Therapy Survey
Between 2008 and 2009, the European Society of Cardiology (ESC)
in cooperation with the European Heart Rhythm Association
(EHRA) and the Heart Failure Association (HFA), conducted a 6
month survey of patients receiving CRT, the results of which were
published in 2009.10 –12 This first CRT Survey was based on data
from 13 countries with 2438 implantations and provided valuable
insights into current clinical practice in this field. Overall large differ-
ences in implantation rates were found across countries with a
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marked underutilization of therapy. However, and unexpectedly, the
survey also showed that large numbers of CRT-P/CRT-D devices
were implanted outside of recommendations in the guidelines.13,14
Thus, a CRT device was frequently implanted in patients with atrial
fibrillation (23%), narrow QRS (,120 ms) (9%), previous devices
(26%), mild symptoms (22% in NYHA class I or II) and in patients
with advanced age (31% ≥ 75 years). In summary, the first CRT
Survey demonstrated that clinicians were exploring indications
broader than those recommended in the ESC Guidelines.
We believe that such heterogeneous CRT implementation prac-
tices across patient groups and countries still exist. Moreover, the im-
portance of optimal implantation techniques to reduce the risk of
complication and of left ventricular lead placements to enhance re-
sponse to CRT has become increasingly clear. Therefore, EHRA
and HFA have now planned a more extensive survey. This Survey,
CRT Survey II, is designed to detect and reflect the substantial
changes in device guideline recommendations recently published
by both EHRA and HFA.8,9 These recommendations emphasize the
importance of QRS duration and morphology, clinical status, and
also provide new indications for CRT in patients requiring upgrades
to CRT, patients with atrial fibrillation and in those who need per-
manent ventricular pacing due to high degree atrioventricular
block.15
Most of the current information available regarding CRT implan-
tations and complications has been obtained from randomized
control trials (RCT) usually performed in relatively high volume
centres with experienced implanters. Randomized control trials
have strict inclusion criteria, and include selected patient groups,
tending to exclude both elderly patients and those with a large
number of co-morbidities. It is estimated that as few as one-third
of patients with heart failure would actually qualify to participate
in a heart failure RCT.16 Thus, extrapolating from the findings
of RCTs to the broad clinical population may not always be
appropriate.
Surveys and registries provide useful data that can complement
RCTs in producing evidence-based medicine.17 Surveys enrol all eli-
gible patient groups, preferably consecutively, including high-risk
patients that tend to be excluded from RCTs and thus are more rep-
resentative of the general clinical population permitting more exten-
sive subgroup comparisons. Surveys and registries can therefore be
used to confirm or refute whether data from RCT can be extrapo-
lated to RCT-excluded patient subgroups. Surveys may also identify
the true magnitude of complications in routine clinical practice and
capture adverse events that may occur in high-risk patient groups.
Variations in patient selection criteria and implantation routines are
identified, permitting both benchmarking and assessment of adher-
ence to current ESC Guidelines.
Design
Participating countries
The HFA and EHRA will invite investigators from 47 ESC member
countries to participate in the survey. Information from the 2014
EHRA White Book18 regarding the number of implanting centres
and CRT devices implanted in 2013 in these countries is listed
in Appendix I. Each country enrolled in the Survey will have a
single national coordinator, selected by the corresponding National
Cardiology Society. The National Coordinator’s role is to recruit
centres and implanters and facilitate the successful performance
of the survey. Each country will retain the rights to publish on
their national data and benchmark internationally. The National
Coordinators will have responsibility for the publication process
of their national data.
Survey population
All hospitalized patients accepted for de novo implantation of a
CRT-P/CRT-D, or for upgrades froman implantable cardioverterde-
fibrillator or permanent pacemaker to a CRT-P/CRT-D, are eligible
for inclusion. Patients should be included consecutively. Ethics ap-
proval for participation in the survey will be obtained in those coun-
tries where it is required.
Data collection and management
The CRT Survey II includes two internet-based questionnaires.
Initially, a one-time site description questionnaire will be completed
by each site prior to inclusion of the first patient. This information
will describe the organization of the device programme at each
site and provide information useful for assessing health resource
utilization. Specifically, it will cover description of hospital type,
the size of the catchment area, the number and type of invasive pro-
cedures and device implantations performed, the cardiac facilities
such as on-site cardiac surgery, invasive laboratory types, types of
imaging equipment employed, the number and speciality of implant-
ing physicians and the follow-up options and routines provided for
patients receiving CRT devices. Importantly, the type and source of
hospital reimbursement will be recorded. An abbreviated summary
of the contents of the one-time site questionnaire can be found in
Appendix II.
The second form is an internet-based electronic case report form
(eCRF) for each patient included in the survey. It will be initiated
prior to implantation of the device to ensure that all consecutive suc-
cessful and non-successful implantations are reported. This stream-
lined eCRF has been revised substantially by the Steering Committee
What’s new?
† The first CRT Survey performed in 2008, demonstrated that
clinicians were exploring indications broader than those
recommended in the ESC Guidelines. Substantial numbers
of patients with mild symptoms, atrial fibrillation, a narrow
QRS complex, a previous device or advanced age received
CRT devices.
† Recent evidence based on randomized clinical trials as well as
updated ESC Guidelines should have a major impact on clinical
practice.
† CRT Survey II will capture clinical and demographic data, de-
scribe current implantation and follow-up practice and
provide information relevant for assessing health care re-
source utilization in connection with CRT.
† The Survey should permit representative benchmarking both
nationally and internationally in 47 ESC member states.
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in collaboration with representatives from the CRT manufacturers
to capture the information that proved most useful in the first
CRT Survey as well as to reflect the changes in clinical practice
that have occurred in response to the most recent European Guide-
line recommendations. The eCRF includes information regarding
patient demographics, aetiology of heart failure, co-morbidities,
pharmacological therapy, electrocardiogram morphology and
QRS duration, imaging information, indication for CRT implantation,
laboratory status, procedural details including left ventricular (LV)
lead position, device programming as well as discharge status, im-
portant peri-procedural or post-procedural complications and
follow-up plans. Importantly and in contrast to the first CRT
Survey, data from unsuccessful CRT implantations will also be
included and identify obstacles for successful implantations of the
LV lead. Vital status at 1 year will be obtained in the majority of
patients. An abbreviated summary of the contents of the eCRF can
be found in Appendix III.
Data collection, management, and analysis in the first CRT Survey
was organized by Institut fur Herzinfarkforschung in Ludwigshafen.
Institut fur Herzinfarkforschung will again organize data management
and perform statistical analyses for CRT Survey II. The centre has an
effective, licensed, online data capture system, which allows data
entry in any local language.
Conclusions
Cardiac Resynchronization Therapy (CRT) Survey II follows on from
the success of the first ESC CRT Survey, which provided valuable in-
formation regarding implantation practices in 13 ESC member coun-
tries. This second Survey will include 47 ESC member countries and
benefit in design from our previous experience. The large volume of
clinical data collected should reflect current selection, implantation
and follow-up practice and provide information relevant for assessing
healthcare resource utilization in connection with CRT devices. The
findings of this Survey should permit representative benchmarking
both nationally and internationally across Europe.
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Appendix I
Number of cardiac resynchronization therapy (CRT) devices
implanted in 2013 by country.
Data from the EHRA White Book for 2014.
(Listed indescendingorderbynumberof implantationsperyear).
Bolded countries were included in the First Survey.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Country Number of centres CRTs per year
Italy 361 12148
Germany 465 8859
France 159 *8605
United Kingdom 109 7762
Poland 25 3000
Continued
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Appendix II
Asummaryof thecontentsof theone-timesitequestionnaire
for CRT Survey II.
Hospital information
† Hospital details, primary contact, implanting physicians
Hospital facilities
† Total number of hospital beds, number of cardiology department
beds
† Type of hospital: university, teaching, community, or private
hospital
† Number of inhabitants of catchment area
† Cardiac surgery on site, angiography/percutaneous coronary
intervention on site
† Total number of catheterization laboratories, dedicated electro-
physiological labs, other sites where devices are implanted,
hybrid/surgical/radiology
Follow-up
† Heart failure clinic for patient follow-up? Dedicated CRT clinic for
follow-up? A remote device monitoring follow-up service? Are all
patients followed-up at implanting centre?
Reimbursement
† Reimbursed for CRT devices? what is the source?(Public health
provider/Private insurance/Private payer)
Cardiology activity profile
† Coronary angiograms in 2014
† Percutaneous coronary intervention procedures in 2014
† CRT-P implanted in 2014
† CRT-D implanted in 2014
† ICD implanted in 2014
† New non-CRT pacemaker implantations in 2014
Number and specialty of CRT implanting physicians in 2014
† Electrophysiologists
† Interventional cardiologists
† Heart failure physicians
† Cardiac surgeons
† General cardiologists
Does your centre participate in
† An active device registry?
† Randomized clinical trials?
† Observational studies?
† A dedicated lead extraction/management program?
Appendix III
A summary of the contents of the electronic case report
form for CRT Survey II.
Demographics
† Date of admission, age, gender, elective admission, referral from
another centre
Heart failure aetiology
† Ischaemic, non-ischaemic, other
† History of revascularization (percutaneous coronary interven-
tion/coronary artery bypass graft)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Continued
Country Number of centres CRTs per year
Spain 130 2545
Netherlands 57 2069
Czech Republic 17 1716
Belgium 35 1221
Israel 20 1216
Austria 18 1178
Russian Federation 42 1012
Denmark 5 1001
Hungary 13 984
Sweden *33 967
Portugal 26 *564
Greece 16 500
Switzerland 31 477
Slovakia 5 452
Finland 14 437
Norway 9 426
Egypt 13 414
Ireland 17 378
Serbia 6 329
Bulgaria 8 260
Kazakhstan 9 209
Romania 17 200
Lithuania 3 165
Slovenia 2 131
Lebanon 5 100
Ukraine 13 89
Croatia 7 81
Morocco 5 75
Estonia 2 70
Algeria 8 64
Latvia 2 63
Belarus 5 54
Georgia 6 40
Bosnia and Herzegovina 2 25
Cyprus 3 25
Luxembourg 1 22
Azerbaijan 2 17
Macedonia FYR 2 16
Malta 1 16
Iceland 1 14
Armenia 2 10
Montenegro 1 10
*Data from 2012.
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Past history and major comorbidity
† Chronic obstructive pulmonary disease, diabetes, myocardial in-
farction, atrial fibrillation, chronic kidney disease, heart failure
(HF) hospitalization during last year, previous device implantation
(PPM/ICD)
Pre-implant clinical evaluation
† NYHA class, weight, height, blood pressure
† Pharmacologic therapy prior to implantation
Pre-implant electrocardiogram
† Heart rate, rhythm, PR interval, paced rhythm, atrioventricular
(AV) block, AV nodal ablation?
Electrocardiogram indication for CRT therapy
† QRS duration and morphology
Clinical indication for CRT
† Device implantation primarily based on treatment of symptoms?
† To improve prognosis? LV dysfunction?
† Indication for an ICD? (primary or secondary prevention?)
† LV dysfunction and bradycardia requiring permanent pacing
Preimplant imaging prior to CRT implantation
† Echo, magnetic resonance imaging, computed tomography,
scintigraphy
† Various indices of LV function and size
Laboratory measurement
† Hb, Na, K, BNP, NT-proBNP, creatinine (eGFR)
Procedure
† Date, type of device, operator, location of procedure, duration,
fluoroscopy time, prophylactic antibiotics, test shock
† Was a venogram performed?
† If LV lead placement is unsuccessful what was main reason?
(coronary sinus not located, no suitable coronary vein, other
complication)
† LV lead type: unipolar, bipolar, multipolar
† LV position evaluation evaluated in bi-plane x-ray projection [left
anterior oblique (LAO) site evaluation: anterior, lateral, posterior,
right anterior oblique (RAO) site evaluation: basal, mid basal,
apical]
Peri-procedural complications
† Death, bleeding, pneumothorax, pericardial tamponade, hae-
mothorax, coronary sinus dissection
Post-procedural complications
† Pocket haematoma, phrenic nerve stimulation, lead dislocation or
displacement, lead malfunction
Post-implant electrocardiogram
† Paced QRS duration
Device programming
† AV/VV programming prior to discharge?
† Availability of remote monitoring?
Discharge status and major adverse events
† Vital status
† Adverse events following implantation during index hospitalization
† (Myocardial infarction, stroke, infection, HF decompensation,
arrhythmias, worsening renal function, other)
What follow-up is planned?
† CRT clinic? HF clinic?
One year follow-up (optional)
† Vital status
† Date of last contact
† Current NYHA class
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